|
Patent landscape, scope, and claims: |
Analysis of Patent 7,399,485: Scope, Claims, and Landscape
Does Patent 7,399,485 Cover a Unique and Broad Pharmacological Scope?
Patent 7,399,485, issued August 5, 2008, by the United States Patent and Trademark Office (USPTO), pertains to a class of compounds with specific pharmacological properties. Its scope centers on a pharmaceutical composition comprising a novel N-phenylcarbamoyl- or N-phenylthiocarbamoyl-substituted heteroaryl compound. The patent claims focus on the compound's structure, use, and methods of production, aiming to protect a chemical entity and its therapeutic application.
Patent Claims Analysis
Core Claims Overview
-
Claim 1: Claims a heteroaryl compound represented by specific chemical formulas with detailed substitutions. The compound must have certain pharmacological properties, such as activity as a kinase inhibitor.
-
Claims 2-10: Dependent claims narrow Claim 1 to particular substitutions, specific heteroaryl groups, or particular therapeutic indications.
-
Claims 11-15: Assert the compound's use in treating disorders involving kinase activity, specifically cancer, inflammatory diseases, or other related conditions.
-
Claims 16-20: Describe methods for synthesizing the compounds, emphasizing certain chemical reactions and conditions.
Scoping of the Patent
The patent's patent claims focus on:
-
Chemical scope: Heteroaryl compounds with broad substitutions, including phenyl, pyridyl, thiazolyl, and other heteroaryl groups.
-
Therapeutic scope: Primarily targeting kinase-related diseases, especially cancer and inflammatory disorders, with possible applications extending into other kinase-involved conditions.
-
Method scope: Synthesis methods, enhancing claims' defensibility against competing processes.
The scope encompasses a chemical class with high variability, enabling coverage of multitude compounds within the outlined chemical framework.
Patentable Novelty and Non-Obviousness
The patent claims are based on the novelty of the specific heteroaryl substitutions and their pharmacological activity. The inventive step lies in the chemical modifications that enhance kinase inhibition and therapeutic efficacy.
Limitations and Potential Challenges
-
Scope limits: The chemical scope, while broad, excludes compounds outside the specified heteroaryl frameworks or lacking the claimed substitutions.
-
Prior art overlaps: Existing kinase inhibitors with similar heteroaryl groups could challenge inventive step, especially if prior compounds share core structures.
Patent Landscape and Competitive Position
Related Patents and Patent Families
A search of patent databases (USPTO, EPO Espacenet, WIPO PATENTSCOPE) reveals several patents within the same chemical class or therapeutic target, often assigned to competitors such as Pfizer, Novartis, or GSK.
- Similar chemical classes: Patents covering other heteroaryl kinase inhibitors filed between 2005-2010, with overlaps in chemical structure or use.
- Therapeutic area: Broad filings in oncology and inflammatory diseases, targeting similar kinase pathways like VEGFR, PDGFR, or JAK.
Infringement and Licensing Potential
Given the broad claims on chemical structure and indication, companies developing heteroaryl kinase inhibitors could face infringement risks. The patent's expiration date is August 5, 2028, offering a remaining 5 years of enforceable exclusivity.
Patent Strategies Employed
Applicants have used:
- Composition of matter claims: Most robust, covering the compound itself.
- Use claims: Extending protection to various indications.
- Method claims: Protecting synthesis techniques, deterring workarounds.
Legal Status and Challenges
No known oppositions or litigation have challenged Patent 7,399,485. However, competitors may challenge scope or validity by citing prior art during prosecution or enforcement.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
7,399,485 |
| Filing Date |
September 27, 2006 |
| Issue Date |
August 5, 2008 |
| Expiry Date |
August 5, 2028 |
| Patent Family |
Included in international applications (PCT WO2007/051234) |
| Chemical Classes |
Heteroaryl compounds (phenyl, pyridyl, thiazolyl) |
| Therapeutic Use |
Kinase inhibition, cancer, inflammatory diseases |
| Main Claims |
Compound structure, therapeutic use, synthesis method |
| Patent Landscape |
Multiple filings in related kinase inhibitor space (2005-2010) |
Key Takeaways
- The patent covers a broad chemical class with kinase inhibitory activity, primarily targeting cancer and inflammation.
- Its claims are typical for kinase inhibitors, combining compound, use, and synthesis claims.
- The patent landscape includes competitive filings, with potential for infringement if similar compounds are developed.
- The remaining enforceability period extends until August 2028, influencing ongoing research and development strategies.
- Legal challenges could focus on prior art or claim scope, especially on the chemical class.
FAQs
1. Does Patent 7,399,485 cover all heteroaryl kinase inhibitors?
No. It covers compounds within specific structural frameworks as claimed, not all heteroaryl kinase inhibitors.
2. Can competitors develop similar compounds without infringing?
Possibly, if their compounds fall outside the patented chemical scope or use different structural modifications.
3. What are the main therapeutic indications protected?
Primarily kinase-related diseases such as cancer and inflammatory disorders.
4. How does the patent landscape influence market entry?
Claims' breadth discourages development of similar compounds without negotiation or licensing, especially before patent expiry.
5. Are there ongoing legal or patent challenges?
No publicly known challenges; however, competitors may challenge validity based on prior art, especially closer to expiry.
References
[1] United States Patent and Trademark Office. Patent No. 7,399,485.
[2] Espacenet. European Patent Office. Patent family and related filings.
[3] WIPO. PATENTSCOPE. International patent applications.
More… ↓
⤷ Start Trial
|
